openPR Logo
Press release

Rising Prevalence of Infectious Diseases Drives the Growth of Gram-Positive Bacterial Infections Market

10-07-2016 08:39 AM CET | Health & Medicine

Press release from: TMR - Research Reports

Rising Prevalence of Infectious Diseases Drives the Growth

Bacteria represents essential class of micro-organisms that play a crucial role in the development of infection of any disease to the human being and animal kingdom. Bacteria are divided into two types on the basis of gram staining test, namely; gram-positive bacteria and gram-negative bacteria.

Gram-positive bacteria retain the gram stain and hence are observed as violet purple colored stains when observed under microscope. These are distinguished from gram-negative bacteria, which are colored with red stains. Gram-positive bacteria represents the major class of bacteria and are responsible for infecting humans and animals with variety of acute and chronic diseases. Gram-positive bacteria are further divided on the basis of their shapes, such as, cocci and bacilli.

Download Exclusive Sample of this Report: http://bit.ly/2dj8jTb

The market of gram-positive bacterial infections is segmented on the basis of various bacteria that belongs to the class, such as, bacillus, lactobacillus, actinomyces, clostridium, staphylococcus, streptococcus, listeria, enterococcus, mycobacterium, and many others.

Further, the market is also segmented on the basis of diseases caused by gram-positive bacteria, such as, tuberculosis and other respiratory diseases, anthrax, newborn meningitis, acne, and many others. Moreover, it is segmented on the basis of antibacterial drugs, such as, B-lactum antibiotics (Penicillin), clavulanic acid (Augmentin), aminoglycosides (Streptomycin), glycopeptides (Vancomycin), polypeptides (Bacitracin), rifamycins (Rifampicin), chloramphenicol, tetracycline and many others.

Additionally, the market is segmented on the basis of geography, such as, North America, Europe, Asia-Pacific and Rest of the World (RoW). At present, North America and Europe are the most prominent markets, owing to growing prevalence of various gram-positive bacterial infections and associated diseases.

However, Asia-Pacific and some countries in RoW region are expected to show lucrative growth in upcoming period, owing to rapidly growing prevalence and awareness about the diseases caused due to gram-positive bacteria and their chronic effects.

The market is expected to show a prominent growth during the forecast period 2014 – 2020. This growth is expected to be driven by factors, such as, increasing prevalence of various gram positive bacterial infections and extensive R&D practices ongoing across the globe. These factors are supported by rising awareness about infections and diseases and increasing medical expenditure. Rising prevalence of infectious diseases is the most important factor that drive the growth of the market to a higher end.

According to the WHO, tuberculosis is the second greatest killer across the globe and killed around 1.3 million people in 2012, throughout the world. Thus, such infections prevalence is an important growth driver of the market. Further, due to extensive R&D practices, a number of drugs and formulations are on the way to enter in the market during the forecast period 2014 -2020. Some of the important pipeline products include LTX-109, PYN-6, RX-P792, XF-70, and TD-1607 amongst others.

In addition, various schemes by the WHO, such as, DOTS and Stop TB Strategy (particular for tuberculosis), helps in increasing awareness amongst the population, that fuels the growth of the market. On the other hand, factors such as government austerity, high cost of treatment and R&D, and ignorance towards the symptoms may hamper the growth of the market to certain extent.

Browse Research Report: http://bit.ly/2dzzFGy

Some of the major players engaged in R&D and commercialization of the products in the Gram-Positive Bacterial Infections market include Basilea Pharmaceuticals Ltd., Cubist Pharmaceuticals, Novabiotics Ltd., TAXIS Pharmaceuticals, Inc., Aphios Corporation, Pfizer, Inc., GSK plc, Theravance, Inc. amongst many others.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rising Prevalence of Infectious Diseases Drives the Growth of Gram-Positive Bacterial Infections Market here

News-ID: 370454 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for R&D

Sales Acceleration Technology Market 2023: Sales and Industry Revenue Forecasts- …
The Sales Acceleration Technology market has witnessed growth from USD XX million to USD XX million from 2017 to 2023. With the CAGR of X.X%, this market is estimated to reach USD XX million in 2029. The report focuses on the Sales Acceleration Technology market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides detailed cost analysis, supply chain. Technological
R&D Incentive Services Market is Booming Worldwide | KPMG, R&D Incentives, Deloi …
The latest report released on Global R&D Incentive Services Market analyses areas where there is still room for improvement. Irrespective of industry, organization size, or geographic location, the R&D Incentive Services Market study suggests that advanced technologies are playing a bigger role than ever before. The assessment provides trend, growth factors and estimates for Global R&D Incentive Services Market forecasted till 2028. Some of the key players profiled are KPMG
Siveco doubles China R&D investment
On July 3, 2019, Siveco China held its half-year management meeting at the prestigious Hellas House in Shanghai, a nod to the company's continuing growth on the Belt & Road. With financial results above target, high customer satisfaction (as shown in the latest audited customer satisfaction survey) and a sales pipeline more promising than ever, the company's management board announced that shareholders have approved its request for additional investment in
R&D Collaborative Projects by GD Rectifiers
GD Rectifiers have extensive experience in collaborative R&D projects and are proud to work with some of the UK’s pioneering power electronic companies to drive design and innovation forward. This R&D service helps drive GD Rectifiers forward as a cutting edge manufacturer embracing fundamental technologies that support product development that contribute to next generation products throughout: renewable energy, embedded systems, smart metrering and the rail industry. Power Assemblies, Controllers and
Noliac is expanding the R&D team
Noliac is looking for two new colleagues for the R&D team in Prague, Czech Republic: A Precision/Fine Mechanics and an Electroengineer. Precision/Fine Mechanics For the R&D team in Prague, Czech Republic, Noliac is looking for a Precision/Fine mechanics to work on modifying existing products and work with developing new. Noliac requires a colleague who: Is mechanically skilled with a focus on very small machinery. Holds a technical high school degree or an apprenticeship
Leiber GmbH further invests in R&D
Since February 2016, Leiber GmbH has been reinforced by Dr med vet Claudia Westfahl - a veterinarian specialized in animal nutrition - as part of the company's strategy to invest in new product developments. With the new position ‘Product Development Animal Nutrition’, Dr Westfahl is responsible for new product development in the field of functional feed ingredients for both pet as well as farm animals. After graduating at the University